A Phase 3 interventional study of CP-690,550 (tofacitinib) and placebo in Juvenile Idiopathic Arthritis, sponsored by Pfizer. Completed at 103 sites in 14 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-04-13.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.
Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is the only one that started in 2016, is one of 4 in phase 3, and was the 8th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 2–17
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 5 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 127 across the 7 interventional studies, 100 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate efficacy, safety and tolerability of tofacitinib in pediatric JIA patients.
This is a randomized withdrawal, double blind, placebo controlled study of pediatric subjects (2 to \<18 years of age) with JIA. The primary objective is to compare the efficacy of tofacitinib versus placebo for the treatment of signs and symptoms of JIA at Week 26 of the double blind phase as measured by the percentage of subjects with disease flare (according to PRCSG/PRINTO Disease Flare criteria) after Week 18 of the open label run in phase.All eligible subjects enrolled in the study will initially receive open label tofacitinib for 18 weeks (run in phase). At the end of the 18 week run in phase, only subjects who achieve at least a JIA ACR 30 response will be randomized to the 26 week double blind, placebo controlled phase. Subjects who do not achieve a JIA ACR 30 response at this time point will be discontinued from the study. In addition, subjects who experience a single episode of disease flare at any time during the study (including the open label run in and double blind phase) will also be discontinued from the study. All subjects participating in this study, including those discontinued from the study, will have the option, if eligible (based on inclusion and exclusion criteria), of enrolling in the tofacitinib JIA long term extension study (A3921145).
Subjects who are eligible for the 26 week double blind phase will be randomized (1:1 ratio) to either active tofacitinib or placebo. For subjects with polyarticular course JIA (ie, extended oligoarthritis, polyarthritis RF+, polyarthritis RF , systemic JIA with active arthritis but without active systemic features), randomization will be stratified by JIA category and baseline CRP (normal, above normal). For subjects with psoriatic and enthesitis related arthritis, randomization will be stratified by JIA category.
Approximately 210 subjects will be enrolled in the open label run in phase. Among subjects with polyarticular course JIA, stratification will target at least 50% with a baseline CRP above the upper limit of normal. The first cohort (ie, polyarticular course JIA) will have at least 170 subjects enrolled in the run in phase with the minimum number of JIA categories as follows: 24 with extended oligoarthritis, 20 with polyarthritis RF+, 62 with polyarthritis RF-, and no minimum for subjects with systemic JIA with active arthritis but without active systemic features. Additional cohorts (ie, psoriatic and enthesitis related arthritis) will include a minimum of 20 subjects with psoriatic arthritis, and 20 subjects with enthesitis related arthritis. The overall target minimum number of subjects to be enrolled in the study by age is as follows: 20 subjects 2 to \<6 years, 20 subjects 6 to \<12 years, and 20 subjects 12 to \<18 years. The duration of subject participation among those who complete the study (without discontinuation) is expected to be approximately 44 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must meet International League Against Rheumatism (ILAR) JIA diagnostic criteria for one of the following categories with active disease for at least 6 weeks:
Subjects with psoriatic or enthesitis related arthritis must have a minimum of 3 active joints (an active joint is defined as a joint with swelling or, in the absence of swelling, limited range of motion accompanied by either pain on motion or tenderness) at screening and baseline to be eligible for study entry.
Treatment with stable doses of a Non Steroidal Anti inflammatory Drug (NSAID) and/or a stable dose of an oral , and/or a stable dose of methotrexate is permitted.
For subjects receiving an oral glucocorticoid: Glucocorticoids may be administered at a maximum dose of 0.2 mg of prednisone equivalent per kilogram per day or 10 mg per day for ≥ 2 weeks before baseline, whichever is lower.
For subjects receiving methotrexate (MTX) treatment: MTX may be administered either orally or parenterally at doses not to exceed 25 mg/wk or 20 mg/m2/week (whichever is lower); participants must have taken MTX for 3 months and be at a stable dose for at least 6 weeks before baseline. Subjects taking MTX must be taking folic acid or folinic acid in accordance with local standards.
For subjects with psoriatic arthritis, the following topical treatments for psoriasis are allowed: non medicated emollients for use over the whole body; topical steroids including hydrocortisone and hydrocortisone acetate ≤1% for the palms, soles, face, and intertriginous areas only; tar, salicylic acid preparations, and shampoos free of corticosteroids are permitted only for the scalp
No evidence or history of untreated or inadequately treated active or latent tuberculosis (TB) infection as evidenced by the following:
If a subject has previously received an adequate course of therapy for either latent (9 months of isoniazid in a locale where rates of primary multi drug resistant TB infection are \<5% or an acceptable alternative regimen) or active (acceptable multi drug regimen) TB infection, neither a PPD test nor a QuantiFERON-Gold®TM test need be obtained. A chest radiograph should be obtained if not done within the 3 months prior to screening. To be considered eligible for the study, the chest radiograph must be negative for active tuberculosis infection.
A subject who is currently being treated for latent TB infection can only be enrolled with confirmation of current incidence rates of multi-drug resistant TB infection, documentation of an adequate treatment regimen, and prior approval of the Sponsor.
6 Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria
Subjects with any of the following characteristics/conditions will not be included in the study:
Infections:
Blood dyscrasias, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights
Drug: CP-690,550 (tofacitinib)
Control arm: matching placebo tablets or solution for tofacitinib
Other: placebo
During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below. During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below. Body Weight (Dosage in tablet \[BID\] or solution \[BID\]): 5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml). Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg.
Also known as: Matching placebo to tofacitinib (same tablet or solution as the active arm).
matching placebo tablet or solution for tofacitinib
Also known as: Placebo for tofacitinib
Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 44
According to PRCSG/PRINTO, disease flare defined as worsening of \>=30 percent(%) in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range of motion accompanied by pain/tenderness), 2)Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a Visual Analog Scale\[VAS\] of 0\[no activity\] to 10\[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0\[very well\] to 10\[very poor\], 5) Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI): 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score,which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) Erythrocyte Sedimentation Rate(ESR).
Time frame: Week 44
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 44
JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Week 44
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Week 44
JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Week 44
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 44
JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Week 44
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Score at Week 44
CHAQ is a valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from double-blind baseline at Week 44 in DI total score is reported.
Time frame: Baseline, Week 44
Open-Label Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 2, 4, 8, 12 and 18
According to PRCSG/PRINTO, disease flare defined as worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
Time frame: Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Percentage of Participants With Disease Flare According to PRCSG/PRINTO Disease Flare Criteria at Week 20, 24, 28, 32, 36 and 40
According to PRCSG/PRINTO, disease flare defined as worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Weeks 20, 24, 28, 32, 36 and 40
Open-Label Phase: Time to Disease Flare
Time to disease flare:time (in days) from first dose of study drug until the day of disease flare in open-label phase. According to PRCSG/PRINTO, disease flare: worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. 6 core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
Time frame: Day 1 up to week 18
Double Blind Phase: Time to Disease Flare
Time to disease flare: time (in days) from first dose of study drug until the day of disease flare in double blind phase. According to PRCSG/PRINTO, disease flare: worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. 6 core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
Time frame: Day 1 of Week 19 up to week 44
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Weeks 2, 4, 8, 12 and 18
JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Double Blind Baseline, Weeks 20, 24, 28, 32, 36 and 40
JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Weeks 2, 4, 8, 12 and 18
JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
Time frame: Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Double Blind Baseline, Weeks 20, 24, 28, 32, 36 and 40
JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Weeks 2, 4, 8, 12 and 18
JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
Time frame: Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Double Blind Baseline (Week 18),Week 20, 24, 28, 32, 36 and 40
JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Week 2, 4, 8, 12 and 18
JIA ACR90 response defined as: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
Time frame: Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
JIA ACR90 response defined as: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Week 2, 4, 8, 12 and 18
JIA ACR100 response defined as: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
Time frame: Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
JIA ACR100 response defined as: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open Label Phase: Change From Baseline in Juvenile Arthritis Disease Activity Score 27 (JADAS-27) C-Reactive Protein (CRP) Score at Weeks 2, 4, 8, 12 and 18
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Change From Double-Blind Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 27 C-Reactive Protein (CRP) Score at Week 20, 24, 28, 32, 36, 40 and 44
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in mg/L and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open Label Phase: Change From Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Week 2, 4, 8, 12 and 18
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
Time frame: Baseline, weeks 2, 4, 8, 12 and 18
Double Blind Phase: Change From Double-Blind Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Weeks 20, 24, 28, 32, 36, 40 and 44
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Percentage of Participants With JADAS-27 CRP Minimum Disease Activity at Weeks 2, 4, 8, 12 and 18
Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for participants with polyarthritis, and less than or equal to 2 for participants with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(maximum of 27 defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
Time frame: Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Percentage of Participants With JADAS-27 CRP Minimum Disease Activity at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for participants with polyarthritis, and less than or equal to 2 for participants with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
Time frame: Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Percentage of Participants With JADAS-27 CRP Inactive Disease Activity at Week 2, 4, 8, 12 and 18
JADAS-27 inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthritis: Inactive Disease: \<=1 and 2) Oligoarthritis (\<4 active joints): Inactive Disease: \<=1. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
Time frame: Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Percentage of Participants With JADAS-27 CRP Inactive Disease Activity at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
JADAS-27 inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthritis: Inactive Disease: \<=1 and 2) Oligoarthritis (\<4 active joints): Inactive Disease: \<=1. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
Time frame: Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
Double Blind Phase: Percentage of Participants With JIA ACR Inactive Disease at Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
JIA ACR Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the Standardized Uveitis Nomenclature (SUN) Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]) score of 'best possible' (score of "0") on the scale used, morning stiffness of \<=15 minutes.
Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Double Blind Phase: Percentage of Participants With Presence of JIA ACR Clinical Remission
JIA ACR Clinical Remission Criteria included: Clinical inactive disease for 6 months continuously while on medications for JIA. Clinical Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the SUN Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]) score of 'best possible' (score of "0") on the scale used, morning stiffness of less than or equal to (\<=) 15 minutes.
Time frame: From Week 18 in double blind phase up to Week 44
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Active Arthritis at Week 2, 4, 8, 12 and 18
Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. The score range of the number of joints is from 0-71.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Active Arthritis at Weeks 20, 24, 28, 32, 36, 40 and 44
Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. Number of joints ranged from 0 to 71.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Limited Range of Motion at Weeks 2, 4, 8, 12 and 18
The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'.
Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Physician Global Evaluation of Disease Activity at Week 2, 4, 8, 12 and 18
Physician global evaluation of disease activity was measured on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'No Activity' and '10' as 'Maximum Activity', higher score indicated more disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at Weeks 20, 24, 28, 32, 36, 40 and 44
Physician global evaluation of disease activity was measured on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'No Activity' and '10' as 'Maximum Activity', higher score indicated more disease activity.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Weeks 2, 4, 8, 12 and 18
The parent/or legal guardian/participant rated the overall well-being on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'Very Well' and '10' as 'Very Poorly', higher scores=more disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Weeks 20, 24, 28, 32, 36, 40 and 44
The parent/or legal guardian/participant rated the overall well-being on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'Very Well' and '10' as 'Very Poorly', higher scores=more disease activity.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Scores at Weeks 2, 4, 8, 12 and 18
CHAQ is a valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from baseline at Weeks 2, 4, 8, 12 and 18 in DI total score is reported.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Scores at Weeks 20, 24, 28, 32, 36, and 40
CHAQ: valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate overall score, participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from double-blind baseline at Weeks 20, 24, 28, 32, 36, and 40 in DI total score is reported.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, and 40
Open-Label Phase: Change From Baseline in Child Health Questionnaire (CHQ) Responses at Week 4 and Week 18
CHQ: 50-item, 14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health and Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.
Time frame: Baseline, Week 4 and Week 18
Double Blind Phase: Change From Double-Blind Baseline in Child Health Questionnaire (CHQ) Responses at Week 44
CHQ: 50-item, 14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health and Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.
Time frame: Double-Blind Baseline (Week 18), Week 44
Open Label Phase: Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Weeks 2, 4, 8, 12 and 18
CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/participant were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase:Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Weeks 20, 24, 28, 32, 36, 40 and 44
CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/participant were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36,40 and 44
Open-Label Phase: Percentage of Participants With Active Uveitis at Baseline
Uveitis is the inflammation of the uvea. Participants were assessed for presence of uveitis (according to Standard Uveitis Nomenclature \[SUN\]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in participant at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported.
Time frame: Baseline
Double Blind Phase: Percentage of Participants With Active Uveitis at Week 24 and Week 44
Uveitis is the inflammation of the uvea. Participants were assessed for presence of uveitis (according to Standard Uveitis Nomenclature \[SUN\]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in participant at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported.
Time frame: Week 24 and Week 44
Open-Label Phase: Change From Baseline in the Tender Entheseal Assessment at Weeks 2, 4, 8, 12 and 18
Participants with enthesitis-related arthritis (ERA) undergo Tender entheseal assessment. Tender entheseal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts \> 0)/number of non-missing tender entheses. If \> 33 tender entheseal counts were missing, total number of tender entheses was defined as missing.
Time frame: Baseline, weeks 2, 4, 8, 12 and 18
Double Blind Phase: Change From Double-Blind Baseline in the Tender Entheseal Assessment at Weeks 20, 24, 28, 32, 36, 40 and 44
Participants with ERA undergo Tender entheseal assessment. Tender entheseal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts \> 0)/number of non-missing tender entheses. If \> 33 tender entheseal counts were missing, total number of tender entheses was defined as missing.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Change From Baseline in the Modified Schober's Test at Week 2, 4, 8, 12 and 18
Participants with ERA undergo Modified Schober's Test. In the Modified Schober's Test, a mark was placed 5 cm below the midpoint of a line that joined the posterior superior iliac spines. Another mark was placed 10 cm above the first. The participant then bent maximally forward with the knees fully extended. The distance between the two marks was then re-measured. The full measurement between the two lines was recorded to the nearest tenth of a centimeter and is reported.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Change From Double Blind Baseline in the Modified Schober's Test at Week 20, 24, 28, 32, 36, 40 and 44
Participants with ERA undergo Modified Schober's Test. In the Modified Schober's Test, a mark was placed 5 cm below the midpoint of a line that joined the posterior superior iliac spines. Another mark was placed 10 cm above the first. The participant then bent maximally forward with the knees fully extended. The distance between the two marks was then re-measured. The full measurement between the two lines was recorded to the nearest tenth of a centimeter and is reported.
Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Change From Baseline in the Overall Back Pain and Nocturnal Back Pain Responses at Week 2, 4, 8, 12 and 18
Participants with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/participant were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/participant using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Change From Double-Blind Baseline in the Overall Back Pain and Nocturnal Back Pain Responses at Week 20, 24, 28, 32, 36, 40 and 44
Participants with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/participant were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/participant using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Changes From Baseline in Percentage of Body Surface Area (BSA) Affected With Psoriasis at Weeks 2, 4, 8, 12 and 18
Percentage of body surface area affected by psoriasis was estimated using the palm method. One of the participant's palm to proximal interphalangeal (PIP) and thumb =\\together represented 1% of total BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% \[10 palms\], Upper extremities = 20% \[20 palms\], Trunk \[axillae and groin\] = 30% \[30 palms\], Lower extremities \[buttocks\] = 40% \[40 palms\]). The number of palms of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Changes From Double Blind Baseline in Body Surface Area (BSA) Affected With Psoriasis at Week 20, 24, 28, 32, 36, 40 and 44
Percentage of body surface area affected by psoriasis was estimated using the palm method. One of the participant's palm to PIP and thumb together represented 1% of total BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% \[10 palms\], Upper extremities = 20% \[20 palms\], Trunk \[axillae and groin\] = 30% \[30 palms\], Lower extremities \[buttocks\] = 40% \[40 palms\]). The number of palms of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Changes From Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Weeks 2, 4, 8, 12 and 18
The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 5 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no symptom to 5=severe, higher score indicates more severity.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase:Change From Double-Blind Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Weeks 20, 24, 28, 32, 36, 40 and 44
The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 5 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no symptom to 5=severe, higher score indicates more severity.
Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Taste Assessment of Tofacitinib Oral Solution on Day 14
Oral solution was given only to participants weighing \<40 kg and to the participants who were unable to swallow tablets. Taste assessment was evaluated using a 5 categories questionnaire. Participants were asked to answer in one of the following categories to describe the taste of oral solution of tofacitinib: dislike very much, dislike a little, not sure, like a little and like very much. Number of participants within each category are reported.
Time frame: Day 14
Open-Label Phase: Number of Participants With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases
Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts: \<500 lymphocytes/ millimeter\^3 (mm), neutrophil counts \<1000 neutrophils/mm\^3, platelet counts \<100,000 platelets/mm\^3, any single hemoglobin value \<8 grams/decilitre (g/dL) and any single hemoglobin value drops \>=2 g/dL below baseline. Number of Participants With serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported.
Time frame: From the first dose of study drug up to Week 18
Double Blind Phase: Number of Participants With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases
Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts \<500 lymphocytes/mm\^3, neutrophil counts \<1000 neutrophils/mm\^3, platelet counts \<100000 platelets/mm\^3, any single hemoglobin (hg) value \<8 g/dL and any single hemoglobin value drops \>=2 g/dL below baseline. Number of Participants With serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported.
Time frame: From the first dose of study drug in double blind up to week 44
Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Pubic Hair)
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Day 1 was summarized and reported using number of participants in each stage.
Time frame: Day 1
Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Pubic Hair)
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males) were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Week 44 was summarized and reported using number of participants in each stage.
Time frame: Week 44
Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Breast Exam)
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. Tanner Stage for Breast at Day 1 was summarized and reported using number of participants in each stage.
Time frame: Day 1
Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Breast Exam)
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. Tanner Stage for Breast at Week 44 was summarized and reported using number of participants in each stage.
Time frame: Week 44
Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Genitalia)
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume \< 4 ml or long axis \< 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: \> 20 ml (or \> 4.5 cm long). Tanner Stage for genitalia at Day 1 was summarized and reported using number of participants in each stage.
Time frame: Day 1
Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Genitalia)
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume \< 4 ml or long axis \< 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: \> 20 ml (or \> 4.5 cm long). Tanner Stage for genitalia at Week 44 was summarized and reported using number of participants in each stage.
Time frame: Week 44
Open-Label Phase: Number of Participants With Laboratory Abnormalities
Criteria: Hemoglobin(Hg),hematocrit erythrocytes(Ery); \<0.8\*lower limit of normal (LLN), Ery. Mean Corpuscular Volume; \<0.9\*LLN, \>1.1\*upper limit of normal (ULN), Platelets; \<0.5\*LLN, \>1.75\*ULN, Leukocytes (leu); \<0.6\*LLN, \>1.5\*ULN, Lymphocytes (Ly), Ly/leu, Neutrophils, Neutrophils/leu \<0.8\*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu \>1.2\*ULN, Ery Sedimentation Rate \>1.5\*ULN. Bilirubin, Indirect Bilirubin \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase, Alkaline Phosphatase \>3.0\*ULN, Albumin \>1.2\*ULN, Creatinine \>1.3\*ULN, HDL Cholesterol (Chol)\<0.8\*LLN, LDL Chol, LDL Chol Friedewald Est PEG \>1.2\*ULN, Triglycerides \>1.3\*ULN, Calcium \<0.9\*LLN, Bicarbonate \<0.9\*LLN, Glucose \>1.5\*ULN, Creatine Kinase \>2.0\*ULN, C Reactive Protein \>1.1\*ULN, Chol \>1.3\*ULN. Urinalysis: Specific Gravity \>1.030, Glucose, Ketones, Protein, Hg, Nitrite, Leu Esterase \>=1, Ery, Leu \>=20, Hyaline Casts \>1.Only those category in which at least 1 participant had data is reported.
Time frame: From the first dose of study drug up to Week 18
Double Blind Phase: Number of Participants With Laboratory Abnormalities
Criteria: Hg, hematocrit Ery; \<0.8\* LLN, Ery. Mean Corpuscular Volume; \<0.9\*LLN, \>1.1\* ULN, Platelets; \<0.5\*LLN, \>1.75\*ULN, leu; \<0.6\*LLN, \>1.5\*ULN, Ly, Ly/leu, Neutrophils, Neutrophils/leu \<0.8\*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu \>1.2\*ULN, Prothrombin Time \>1.1\*ULN, Ery Sedimentation Rate \>1.5\*ULN. Bilirubin, Direct Bilirubin, Indirect Bilirubin \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase (GGT), Alkaline Phosphatase \>3.0\*ULN, Albumin \>1.2\*ULN, Creatinine \>1.3\*ULN, HDL Cholesterol (Chol)\<0.8\*LLN, LDL Chol, LDL Chol Friedewald Est PEG \>1.2\*ULN, Triglycerides \>1.3\*ULN, Calcium \<0.9\*LLN, Bicarbonate \<0.9\*LLN, Glucose \>1.5\*ULN, Creatine Kinase \>2.0\*ULN, C Reactive Protein \>1.1\*ULN, Chol \>1.3\*ULN. Urinalysis: Specific Gravity \>1.030, pH \>8, urine Glucose, Ketones, Protein, Hg, Nitrite, Leu Esterase \>=1, Ery, Leu \>=20, Hyaline Casts \>1.Only those category in which at least 1 participant had data is reported.
Time frame: From the first dose of study drug in double blind up to Week 44
Open-Label Phase: Number of Participants With Physical Examination Abnormalities
Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 18
Double Blind Phase: Number of Participants With Physical Examination Abnormalities
Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion.
Time frame: Weeks 18, 20, 24, 28, 32, 36, 40 and 44
Open-Label Phase: Number of Participants With Vital Sign Abnormalities
Vital Sign Abnormalities criteria included: sitting diastolic blood pressure millimeters of Mercury (mmHG) of \<50 mmHg, sitting pulse rate beats per minute (bpm) of \<40 or 120 bpm, sitting systolic blood pressure (mmHG) of \<90 mmHg, supine diastolic blood pressure (mmHG) of \<50 mmHg, supine pulse rate (BPM) of \<40 bpm or \>120 bpm, supine systolic blood pressure (mmHG) of 90 mmHg.
Time frame: From the first dose of study drug up to Week 18
Double Blind Phase: Number of Participants With Vital Sign Abnormalities
Vital Sign Abnormalities criteria included: diastolic blood pressure (mmHG) of \<50 mmHg, Pulse rate (BPM) of \<40 bpm or \>120 bpm, sitting diastolic blood pressure (mmHG) of \<50 mmHg, sitting pulse rate beats per minute (bpm) of \<40 bpm or \>120 bpm, sitting systolic blood pressure (mmHG) of \<90 mmHg, supine diastolic blood pressure (mmHG) of \<50 mmHg, supine pulse rate (BPM) of \<40 bpm or \>120 bpm, supine systolic blood pressure (mmHG) of \<90 mmHg, systolic blood pressure (mmHG) of \<90 mmHg.
Time frame: From the first dose of study drug in double blind up to week 44
Open-Label Phase: Number of Participants With Change From Baseline in Vital Sign Measures
Change in vital Signs included: Sitting diastolic blood pressure \[mmHG\]: \>=20mmHg increase from baseline (IFB) and \>= 20mmHg decrease from baseline (DFB). Sitting systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB. Supine diastolic blood pressure mmHG: \>= 20mmHg IFB and \>= 20mmHg DFB. Supine systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB.
Time frame: From the first dose of study drug up to Week 18
Double Blind Phase: Number of Participants With Change From Baseline in Vital Sign Measures
Change in vital Signs included: Sitting diastolic blood pressure (mmHG): \>=20mmHg IFB and \>= 20mmHg DFB. Sitting systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB. Supine diastolic blood pressure mmHG: \>= 20mmHg IFB and \>= 20mmHg DFB. Supine systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB.
Time frame: From the first dose of study drug in double blind up to week 44
| Milestone | Tofacitinib: Open-Label Phase | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|---|
| Started | 225 | 0 | 0 |
| Treated | 225 | 0 | 0 |
| Completed | 185 | 0 | 0 |
| Not completed | 40 | 0 | 0 |
| Withdrew: Adverse event | 12 | 0 | 0 |
| Withdrew: Insufficient clinical response | 21 | 0 | 0 |
| Withdrew: Other | 3 | 0 | 0 |
| Withdrew: Protocol deviation | 4 | 0 | 0 |
| Milestone | Tofacitinib: Open-Label Phase | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|---|
| Started | 0 | 88 | 85 |
| Treated | 0 | 88 | 85 |
| Completed | 0 | 61 | 38 |
| Not completed | 0 | 27 | 47 |
| Withdrew: Adverse event | 0 | 2 | 2 |
| Withdrew: Insufficient clinical response | 0 | 22 | 44 |
| Withdrew: Other | 0 | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 |
| Withdrew: Medication error without associated aes | 0 | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 | 0 |
According to PRCSG/PRINTO, disease flare defined as worsening of \>=30 percent(%) in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range of motion accompanied by pain/tenderness), 2)Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a Visual Analog Scale\[VAS\] of 0\[no activity\] to 10\[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0\[very well\] to 10\[very poor\], 5) Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI): 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score,which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) Erythrocyte Sedimentation Rate(ESR).
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 44 | 29.17 | 52.86 |
JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 44 | 66.67 | 47.14 |
JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Week 44 | 70.83 | 47.14 |
JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 44 | 54.17 | 37.14 |
CHAQ is a valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from double-blind baseline at Week 44 in DI total score is reported.
| units on a scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Score at Week 44 | -0.09 ± 0.04 | 0.03 ± 0.04 |
According to PRCSG/PRINTO, disease flare defined as worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | 0.54 |
| Week 4 | 3.83 |
| Week 8 | 5.14 |
| Week 12 | 7.23 |
| Week 18 | 8.44 |
According to PRCSG/PRINTO, disease flare defined as worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 9.72 | 11.43 |
| Week 24 | 12.50 | 31.43 |
| Week 28 | 18.06 | 37.14 |
| Week 32 | 23.61 | 45.71 |
| Week 36 | 25.00 | 48.57 |
| Week 40 | 27.78 | 52.86 |
Time to disease flare:time (in days) from first dose of study drug until the day of disease flare in open-label phase. According to PRCSG/PRINTO, disease flare: worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. 6 core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
| days | Tofacitinib: Open-Label Phase |
|---|---|
| Open-Label Phase: Time to Disease Flare | NA (NA to NA) |
Time to disease flare: time (in days) from first dose of study drug until the day of disease flare in double blind phase. According to PRCSG/PRINTO, disease flare: worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. 6 core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
| days | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Phase: Time to Disease Flare | NA (NA to NA) | 155.0 (86.0 to NA) |
JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | 45.11 |
| Week 4 | 68.31 |
| Week 8 | 79.66 |
| Week 12 | 85.63 |
| Week 18 | 92.21 |
JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Baseline (Week 18) | 100.00 | 100.00 |
| Week 20 | 88.89 | 82.86 |
| Week 24 | 86.11 | 68.57 |
| Week 28 | 80.56 | 61.43 |
| Week 32 | 76.39 | 52.86 |
| Week 36 | 73.61 | 48.57 |
| Week 40 | 70.83 | 47.14 |
JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | 20.11 |
| Week 4 | 44.81 |
| Week 8 | 62.71 |
| Week 12 | 71.86 |
| Week 18 | 83.77 |
JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Baseline (Week 18) | 90.28 | 91.43 |
| Week 20 | 81.94 | 74.29 |
| Week 24 | 80.56 | 58.57 |
| Week 28 | 73.61 | 55.71 |
| Week 32 | 69.44 | 44.29 |
| Week 36 | 68.06 | 47.14 |
| Week 40 | 68.06 | 45.71 |
JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | 7.61 |
| Week 4 | 16.94 |
| Week 8 | 36.16 |
| Week 12 | 46.71 |
| Week 18 | 61.04 |
JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Baseline (Week 18) | 68.06 | 64.29 |
| Week 20 | 58.33 | 55.71 |
| Week 24 | 58.33 | 44.29 |
| Week 28 | 54.17 | 47.14 |
| Week 32 | 56.94 | 38.57 |
| Week 36 | 54.17 | 34.29 |
| Week 40 | 54.17 | 34.29 |
JIA ACR90 response defined as: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | 0 |
| Week 4 | 3.83 |
| Week 8 | 11.30 |
| Week 12 | 20.96 |
| Week 18 | 33.12 |
JIA ACR90 response defined as: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Baseline (Week 18) | 33.33 | 38.57 |
| Week 20 | 34.72 | 25.71 |
| Week 24 | 37.50 | 28.57 |
| Week 28 | 36.11 | 27.14 |
| Week 32 | 38.89 | 22.86 |
| Week 36 | 38.89 | 20.00 |
| Week 40 | 34.72 | 22.86 |
| Week 44 | 34.72 | 21.43 |
JIA ACR100 response defined as: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | 0.0 |
| Week 4 | 2.19 |
| Week 8 | 8.47 |
| Week 12 | 14.37 |
| Week 18 | 21.43 |
JIA ACR100 response defined as: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Baseline (Week 18) | 15.28 | 31.43 |
| Week 20 | 27.78 | 17.14 |
| Week 24 | 27.78 | 24.29 |
| Week 28 | 26.39 | 24.29 |
| Week 32 | 27.78 | 21.43 |
| Week 36 | 30.56 | 18.57 |
| Week 40 | 29.17 | 20.00 |
| Week 44 | 29.17 | 17.14 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -6.35 ± 5.44 |
| Week 4 | -9.89 ± 6.54 |
| Week 8 | -12.47 ± 7.51 |
| Week 12 | -14.33 ± 6.96 |
| Week 18 | -15.80 ± 7.12 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in mg/L and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
| score on scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.27 ± 0.64 | 2.33 ± 0.64 |
| Week 24 | 0.83 ± 0.95 | 4.46 ± 0.97 |
| Week 28 | 0.51 ± 0.91 | 4.36 ± 0.97 |
| Week 32 | 0.16 ± 0.73 | 3.46 ± 0.81 |
| Week 36 | 0.34 ± 1.09 | 6.55 ± 1.22 |
| Week 40 | 0.85 ± 1.13 | 7.11 ± 1.26 |
| Week 44 | 0.03 ± 0.91 | 4.39 ± 1.00 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -6.38 ± 5.52 |
| Week 4 | -10.14 ± 6.63 |
| Week 8 | -12.60 ± 7.60 |
| Week 12 | -14.54 ± 6.90 |
| Week 18 | -15.94 ± 7.17 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
| score on scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.62 ± 0.62 | 2.45 ± 0.62 |
| Week 24 | 0.92 ± 0.90 | 4.33 ± 0.92 |
| Week 28 | 0.64 ± 0.86 | 4.22 ± 0.90 |
| Week 32 | 0.26 ± 0.75 | 3.67 ± 0.81 |
| Week 36 | 0.60 ± 1.06 | 6.26 ± 1.17 |
| Week 40 | 0.73 ± 1.05 | 6.35 ± 1.15 |
| Week 44 | 0.09 ± 0.91 | 4.50 ± 0.97 |
Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for participants with polyarthritis, and less than or equal to 2 for participants with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(maximum of 27 defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Baseline | 0 |
| Week 2 | 2.19 |
| Week 4 | 9.29 |
| Week 8 | 20.45 |
| Week 12 | 29.09 |
| Week 18 | 44.16 |
Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for participants with polyarthritis, and less than or equal to 2 for participants with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Baseline (Week 18) | 48.61 | 47.14 |
| Week 20 | 45.83 | 35.71 |
| Week 24 | 47.22 | 34.29 |
| Week 28 | 47.22 | 35.71 |
| Week 32 | 40.28 | 32.86 |
| Week 36 | 44.44 | 30.00 |
| Week 40 | 45.83 | 31.43 |
| Week 44 | 47.22 | 32.86 |
JADAS-27 inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthritis: Inactive Disease: \<=1 and 2) Oligoarthritis (\<4 active joints): Inactive Disease: \<=1. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | 0 |
| Week 4 | 0 |
| Week 8 | 2.84 |
| Week 12 | 3.64 |
| Week 18 | 7.79 |
JADAS-27 inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthritis: Inactive Disease: \<=1 and 2) Oligoarthritis (\<4 active joints): Inactive Disease: \<=1. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Baseline (Week 18) | 6.94 | 10.00 |
| Week 20 | 9.72 | 2.86 |
| Week 24 | 12.50 | 5.71 |
| Week 28 | 9.72 | 7.14 |
| Week 32 | 11.11 | 5.71 |
| Week 36 | 16.67 | 7.14 |
| Week 40 | 18.06 | 7.14 |
| Week 44 | 18.06 | 10.00 |
JIA ACR Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the Standardized Uveitis Nomenclature (SUN) Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]) score of 'best possible' (score of "0") on the scale used, morning stiffness of \<=15 minutes.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Baseline (Week 18) | 9.72 | 27.14 |
| Week 20 | 15.28 | 15.71 |
| Week 24 | 20.83 | 21.43 |
| Week 28 | 19.44 | 18.57 |
| Week 32 | 22.22 | 20.00 |
| Week 36 | 26.39 | 17.14 |
| Week 40 | 26.39 | 14.29 |
| Week 44 | 26.39 | 17.14 |
JIA ACR Clinical Remission Criteria included: Clinical inactive disease for 6 months continuously while on medications for JIA. Clinical Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the SUN Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]) score of 'best possible' (score of "0") on the scale used, morning stiffness of less than or equal to (\<=) 15 minutes.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Double Blind Phase: Percentage of Participants With Presence of JIA ACR Clinical Remission | 4.17 | 4.29 |
Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. The score range of the number of joints is from 0-71.
| joints with active arthritis | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -4.54 ± 5.33 |
| Week 4 | -7.21 ± 6.36 |
| Week 8 | -8.62 ± 7.04 |
| Week 12 | -9.76 ± 6.76 |
| Week 18 | -10.29 ± 6.79 |
Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. Number of joints ranged from 0 to 71.
| joints with active arthritis | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.21 ± 0.48 | 1.07 ± 0.49 |
| Week 24 | 0.69 ± 0.71 | 2.11 ± 0.72 |
| Week 28 | 0.46 ± 0.61 | 2.13 ± 0.64 |
| Week 32 | 0.19 ± 0.48 | 1.36 ± 0.51 |
| Week 36 | 0.52 ± 0.85 | 4.50 ± 0.92 |
| Week 40 | 0.91 ± 0.85 | 4.48 ± 0.93 |
| Week 44 | 0.55 ± 0.74 | 2.79 ± 0.77 |
The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'.
| joints with limited range of motion | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -2.52 ± 4.21 |
| Week 4 | -3.56 ± 5.68 |
| Week 8 | -4.53 ± 5.65 |
| Week 12 | -5.09 ± 5.79 |
| Week 18 | -5.77 ± 5.82 |
The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'.
| joints with limited range of motion | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.38 ± 0.20 | 0.64 ± 0.19 |
| Week 24 | 0.50 ± 0.28 | 1.19 ± 0.29 |
| Week 28 | 0.68 ± 0.35 | 1.63 ± 0.37 |
| Week 32 | 0.61 ± 0.32 | 1.40 ± 0.34 |
| Week 36 | 0.47 ± 0.31 | 1.48 ± 0.34 |
| Week 40 | 0.41 ± 0.34 | 1.49 ± 0.39 |
| Week 44 | 0.38 ± 0.29 | 1.20 ± 0.34 |
Physician global evaluation of disease activity was measured on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'No Activity' and '10' as 'Maximum Activity', higher score indicated more disease activity.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -1.81 ± 1.52 |
| Week 4 | -2.78 ± 1.84 |
| Week 8 | -3.51 ± 1.83 |
| Week 12 | -4.04 ± 1.88 |
| Week 18 | -4.54 ± 1.92 |
Physician global evaluation of disease activity was measured on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'No Activity' and '10' as 'Maximum Activity', higher score indicated more disease activity.
| score on scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.28 ± 0.20 | 0.82 ± 0.20 |
| Week 24 | 0.24 ± 0.24 | 1.08 ± 0.24 |
| Week 28 | 0.12 ± 0.21 | 0.92 ± 0.92 |
| Week 32 | -0.03 ± 0.20 | 0.86 ± 0.22 |
| Week 36 | 0.14 ± 0.28 | 1.56 ± 0.32 |
| Week 40 | 0.02 ± 0.28 | 1.64 ± 0.32 |
| Week 44 | -0.16 ± 0.29 | 1.42 ± 0.34 |
The parent/or legal guardian/participant rated the overall well-being on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'Very Well' and '10' as 'Very Poorly', higher scores=more disease activity.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -0.94 ± 1.95 |
| Week 4 | -1.47 ± 1.92 |
| Week 8 | -1.90 ± 2.20 |
| Week 12 | -2.30 ± 2.15 |
| Week 18 | -2.68 ± 2.33 |
The parent/or legal guardian/participant rated the overall well-being on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'Very Well' and '10' as 'Very Poorly', higher scores=more disease activity.
| score on scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | -0.04 ± 0.18 | 0.38 ± 0.18 |
| Week 24 | -0.03 ± 0.22 | 0.91 ± 0.22 |
| Week 28 | -0.11 ± 0.24 | 0.72 ± 0.26 |
| Week 32 | -0.15 ± 0.24 | 0.82 ± 0.26 |
| Week 36 | -0.22 ± 0.21 | 0.31 ± 0.24 |
| Week 40 | -0.24 ± 0.24 | 0.39 ± 0.27 |
| Week 44 | -0.49 ± 0.22 | 0.24 ± 0.24 |
CHAQ is a valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from baseline at Weeks 2, 4, 8, 12 and 18 in DI total score is reported.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -0.15 ± 0.41 |
| Week 4 | -0.23 ± 0.42 |
| Week 8 | -0.36 ± 0.46 |
| Week 12 | -0.41 ± 0.53 |
| Week 18 | -0.49 ± 0.57 |
CHAQ: valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate overall score, participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from double-blind baseline at Weeks 20, 24, 28, 32, 36, and 40 in DI total score is reported.
| score on scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.05 ± 0.04 | 0.08 ± 0.04 |
| Week 24 | 0.01 ± 0.03 | 0.08 ± 0.04 |
| Week 28 | -0.01 ± 0.04 | 0.09 ± 0.04 |
| Week 32 | 0.01 ± 0.04 | 0.10 ± 0.05 |
| Week 36 | -0.04 ± 0.04 | 0.08 ± 0.05 |
| Week 40 | -0.05 ± 0.04 | 0.06 ± 0.05 |
CHQ: 50-item, 14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health and Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 4: Global health | 13.86 ± 22.40 |
| Week 18: Global health | 21.28 ± 22.79 |
| Week 4: Physical functioning | 11.83 ± 24.47 |
| Week 18: Physical functioning | 21.44 ± 26.78 |
| Week 4: Social limitations: emotional | 8.12 ± 29.29 |
| Week 18: Social limitations: emotional | 14.62 ± 30.18 |
| Week 4: Social limitations: physical | 13.45 ± 31.12 |
| Week 18: Social limitations: physical | 20.81 ± 32.53 |
| Week 4: Bodily pain | 19.42 ± 21.14 |
| Week 18: Bodily pain | 30.60 ± 22.79 |
| Week 4: Behavior | 3.06 ± 12.86 |
| Week 18: Behavior | 5.70 ± 12.91 |
| Week 4: Global behavior | 7.40 ± 23.27 |
| Week 18: Global behavior | 9.30 ± 24.97 |
| Week 4: Mental health | 6.43 ± 15.68 |
| Week 18: Mental health | 6.74 ± 16.06 |
| Week 4: Self esteem | 2.42 ± 19.47 |
| Week 18: Self esteem | 8.45 ± 17.35 |
| Week 4: General health | 4.20 ± 13.50 |
| Week 18: General health | 7.02 ± 14.31 |
| Week 4: Change in Health | 0.86 ± 1.20 |
| Week 18: Change in Health | 1.70 ± 1.32 |
| Week 4: Emotional impact on parent | 9.02 ± 26.30 |
| Week 18: Emotional impact on parent | 15.38 ± 29.35 |
| Week 4: Time impact on parent | 6.17 ± 24.64 |
| Week 18: Time impact on parent | 9.99 ± 23.38 |
| Week 4: Family activities | 5.19 ± 15.15 |
| Week 18: Family activities | 9.59 ± 19.63 |
| Week 4: Family cohesion | 2.78 ± 21.80 |
| Week 18: Family cohesion | 3.62 ± 18.81 |
| Week 4: Physical Health Summary | 8.12 ± 11.18 |
| Week 18: Physical Health Summary | 13.36 ± 12.57 |
| Week 4: Psychosocial Health Summary | 2.46 ± 8.13 |
| Week 18: Psychosocial Health Summary | 4.20 ± 8.41 |
CHQ: 50-item, 14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health and Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.
| score on a scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Global health | 5.46 ± 2.83 | 1.66 ± 3.72 |
| Physical functioning | 1.45 ± 3.16 | -1.82 ± 3.92 |
| Social Limitations: Emotional | 1.78 ± 3.53 | -3.69 ± 4.36 |
| Social Limitations: Physical | -3.08 ± 4.03 | -10.29 ± 5.04 |
| Bodily Pain | 6.34 ± 3.13 | -1.91 ± 3.91 |
| Behavior | 0.78 ± 2.09 | 4.20 ± 2.57 |
| Global Behavior | -2.61 ± 2.89 | 1.04 ± 3.54 |
| Mental Health | 0.41 ± 2.53 | 3.88 ± 3.12 |
| Self Esteem | 1.48 ± 3.29 | 0.76 ± 4.07 |
| General Health | 7.91 ± 1.84 | 6.14 ± 2.26 |
| Change in Health | 0.07 ± 0.10 | 0.09 ± 0.12 |
| Emotional Impact on Parent | 9.55 ± 4.32 | 0.58 ± 5.35 |
| Time Impact on Parent | -3.83 ± 2.92 | 2.89 ± 3.62 |
| Family Activities | 0.01 ± 2.39 | 8.61 ± 2.95 |
| Family Cohesion | 6.04 ± 3.18 | 3.45 ± 3.92 |
| Physical Health Summary | 1.67 ± 1.48 | -1.81 ± 1.85 |
| Psychosocial Health Summary | 0.64 ± 1.22 | 1.39 ± 1.52 |
CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/participant were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -1.32 ± 2.10 |
| Week 4 | -2.06 ± 2.16 |
| Week 8 | -2.38 ± 2.40 |
| Week 12 | -2.72 ± 2.28 |
| Week 18 | -3.04 ± 2.57 |
CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/participant were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.
| score on scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.08 ± 0.20 | 0.40 ± 0.20 |
| Week 24 | -0.01 ± 0.24 | 0.94 ± 0.24 |
| Week 28 | -0.23 ± 0.24 | 0.64 ± 0.25 |
| Week 32 | 0.07 ± 0.27 | 1.06 ± 0.29 |
| Week 36 | -0.21 ± 0.21 | 0.32 ± 0.24 |
| Week 40 | -0.22 ± 0.24 | 0.49 ± 0.26 |
| Week 44 | -0.36 ± 0.23 | 0.44 ± 0.25 |
Uveitis is the inflammation of the uvea. Participants were assessed for presence of uveitis (according to Standard Uveitis Nomenclature \[SUN\]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in participant at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported.
| percentage of participants | Tofacitinib: Open-Label Phase |
|---|---|
| Open-Label Phase: Percentage of Participants With Active Uveitis at Baseline | 0.0 |
Uveitis is the inflammation of the uvea. Participants were assessed for presence of uveitis (according to Standard Uveitis Nomenclature \[SUN\]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in participant at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported.
| percentage of participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 24: Present | 0.0 | 1.2 |
| Week 44: Present | 0.0 | 0.0 |
Participants with enthesitis-related arthritis (ERA) undergo Tender entheseal assessment. Tender entheseal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts \> 0)/number of non-missing tender entheses. If \> 33 tender entheseal counts were missing, total number of tender entheses was defined as missing.
| tender entheses score | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -1.57 ± 3.61 |
| Week 4 | -2.52 ± 3.92 |
| Week 8 | -3.05 ± 4.45 |
| Week 12 | -3.15 ± 4.93 |
| Week 18 | -3.50 ± 4.70 |
Participants with ERA undergo Tender entheseal assessment. Tender entheseal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts \> 0)/number of non-missing tender entheses. If \> 33 tender entheseal counts were missing, total number of tender entheses was defined as missing.
| tender entheses score | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.00 ± 0.87 | 0.86 ± 2.61 |
| Week 24 | -1.00 ± 3.46 | 0.40 ± 2.19 |
| Week 28 | -0.43 ± 2.57 | -0.75 ± 0.96 |
| Week 32 | 0.33 ± 1.97 | 0.00 ± 0.82 |
| Week 36 | -0.83 ± 2.04 | 0.33 ± 0.58 |
| Week 40 | -2.00 ± 4.47 | 0.33 ± 0.58 |
| Week 44 | -2.00 ± 5.66 | -0.33 ± 0.58 |
Participants with ERA undergo Modified Schober's Test. In the Modified Schober's Test, a mark was placed 5 cm below the midpoint of a line that joined the posterior superior iliac spines. Another mark was placed 10 cm above the first. The participant then bent maximally forward with the knees fully extended. The distance between the two marks was then re-measured. The full measurement between the two lines was recorded to the nearest tenth of a centimeter and is reported.
| centimeter (cm) | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -0.35 ± 1.02 |
| Week 4 | -0.20 ± 1.03 |
| Week 8 | -0.12 ± 1.15 |
| Week 12 | 0.02 ± 1.05 |
| Week 18 | 0.29 ± 1.08 |
Participants with ERA undergo Modified Schober's Test. In the Modified Schober's Test, a mark was placed 5 cm below the midpoint of a line that joined the posterior superior iliac spines. Another mark was placed 10 cm above the first. The participant then bent maximally forward with the knees fully extended. The distance between the two marks was then re-measured. The full measurement between the two lines was recorded to the nearest tenth of a centimeter and is reported.
| cm | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | -0.46 ± 1.61 | -0.28 ± 0.47 |
| Week 24 | -0.44 ± 1.27 | -0.35 ± 0.54 |
| Week 28 | 0.32 ± 1.38 | -0.17 ± 0.57 |
| Week 32 | 0.42 ± 1.84 | 0.63 ± 1.26 |
| Week 36 | -0.53 ± 0.84 | 0.05 ± 0.21 |
| Week 40 | 0.57 ± 1.62 | 0.85 ± 0.64 |
| Week 44 | 0.50 ± 0.87 | 1.05 ± 2.47 |
Participants with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/participant were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/participant using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2: Nocturnal Back Pain | -1.21 ± 3.10 |
| Week 4: Nocturnal Back Pain | -1.33 ± 3.44 |
| Week 8: Nocturnal Back Pain | -1.80 ± 3.18 |
| Week 12: Nocturnal Back Pain | -2.30 ± 2.63 |
| Week 18: Nocturnal Back Pain | -1.98 ± 2.94 |
| Week 2: Overall back pain | -1.81 ± 2.89 |
| Week 4: Overall back pain | -1.86 ± 3.29 |
| Week 8:Overall back pain | -2.65 ± 2.72 |
| Week 12:Overall back pain | -3.20 ± 2.54 |
| Week 18: Overall back pain | -3.30 ± 2.45 |
Participants with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/participant were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/participant using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain.
| score on scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20: Nocturnal Back Pain | -0.17 ± 0.87 | 0.57 ± 0.93 |
| Week 24: Nocturnal Back Pain | -1.06 ± 1.96 | 0.10 ± 0.42 |
| Week 28: Nocturnal Back Pain | -0.79 ± 2.00 | 0.00 ± 0.41 |
| Week 32: Nocturnal Back Pain | -1.58 ± 1.63 | 0.38 ± 0.63 |
| Week 36: Nocturnal Back Pain | -0.75 ± 2.27 | 0.17 ± 0.29 |
| Week 40: Nocturnal Back Pain | -2.00 ± 2.26 | 0.17 ± 0.29 |
| Week 44: Nocturnal Back Pain | -0.80 ± 2.20 | 0.17 ± 0.29 |
| Week 20: Overall back pain | 0.28 ± 1.89 | 0.57 ± 1.40 |
| Week 24: Overall back pain | 0.39 ± 2.10 | 0.00 ± 0.79 |
| Week 28: Overall back pain | 0.00 ± 2.60 | -0.25 ± 0.29 |
| Week 32:Overall back pain | -1.75 ± 2.25 | -0.13 ± 0.48 |
| Week 36: Overall back pain | 0.17 ± 1.29 | -0.50 ± 0.87 |
| Week 40: Overall back pain | 0.30 ± 1.79 | -0.50 ± 0.87 |
| Week 44: Overall back pain | -0.10 ± 3.45 | -0.50 ± 0.87 |
Percentage of body surface area affected by psoriasis was estimated using the palm method. One of the participant's palm to proximal interphalangeal (PIP) and thumb =\\together represented 1% of total BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% \[10 palms\], Upper extremities = 20% \[20 palms\], Trunk \[axillae and groin\] = 30% \[30 palms\], Lower extremities \[buttocks\] = 40% \[40 palms\]). The number of palms of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
| percentage of BSA | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | 0.55 ± 4.70 |
| Week 4 | -1.03 ± 2.49 |
| Week 8 | -0.29 ± 6.11 |
| Week 12 | -0.36 ± 5.93 |
| Week 18 | -0.46 ± 6.48 |
Percentage of body surface area affected by psoriasis was estimated using the palm method. One of the participant's palm to PIP and thumb together represented 1% of total BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% \[10 palms\], Upper extremities = 20% \[20 palms\], Trunk \[axillae and groin\] = 30% \[30 palms\], Lower extremities \[buttocks\] = 40% \[40 palms\]). The number of palms of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
| percentage of BSA | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | -0.50 ± 1.22 | 0.28 ± 0.70 |
| Week 24 | -0.14 ± 0.38 | 0.85 ± 1.71 |
| Week 28 | -4.20 ± 8.84 | 0.33 ± 0.58 |
| Week 32 | -0.60 ± 1.34 | 1.67 ± 2.89 |
| Week 36 | -4.20 ± 8.90 | 1.33 ± 2.31 |
| Week 40 | -4.60 ± 8.71 | 0.67 ± 1.15 |
| Week 44 | -4.60 ± 8.71 | -0.05 ± 0.07 |
The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 5 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no symptom to 5=severe, higher score indicates more severity.
| score on scale | Tofacitinib: Open-Label Phase |
|---|---|
| Week 2 | -0.05 ± 0.39 |
| Week 4 | -0.42 ± 0.84 |
| Week 8 | -0.29 ± 0.92 |
| Week 12 | -0.56 ± 0.86 |
| Week 18 | -0.56 ± 1.03 |
The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 5 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no symptom to 5=severe, higher score indicates more severity.
| score on scale | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Week 20 | 0.14 ± 0.38 | 0.00 ± 0.00 |
| Week 24 | 0.14 ± 0.38 | 0.38 ± 0.52 |
| Week 28 | 0.20 ± 0.45 | 0.33 ± 0.58 |
| Week 32 | 0.00 ± 0.00 | 0.33 ± 0.58 |
| Week 36 | 0.00 ± 0.00 | 0.33 ± 0.58 |
| Week 40 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 44 | 0.00 ± 0.00 | -0.50 ± 0.71 |
Oral solution was given only to participants weighing \<40 kg and to the participants who were unable to swallow tablets. Taste assessment was evaluated using a 5 categories questionnaire. Participants were asked to answer in one of the following categories to describe the taste of oral solution of tofacitinib: dislike very much, dislike a little, not sure, like a little and like very much. Number of participants within each category are reported.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Dislike Very Much | 4 |
| Dislike a Little | 8 |
| Not Sure | 6 |
| Like a Little | 32 |
| Like Very Much | 34 |
Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts: \<500 lymphocytes/ millimeter\^3 (mm), neutrophil counts \<1000 neutrophils/mm\^3, platelet counts \<100,000 platelets/mm\^3, any single hemoglobin value \<8 grams/decilitre (g/dL) and any single hemoglobin value drops \>=2 g/dL below baseline. Number of Participants With serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Serious Infections | 3 |
| Cytopenia: Lymphocyte counts <500 lymphocytes/mm^3 | 1 |
| Cytopenia:Neutrophil counts <1000 neutrophils/mm^3 | 4 |
| Cytopenia: Platelet counts <100,000 platelets/mm^3 | 1 |
| Cytopenia: Any single hg value <8 g/dL | 1 |
| Cytopenia:Any hg value drops>=2g/dL below baseline | 17 |
| Malignancies | 0 |
| Cardiovascular Diseases | 0 |
Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts \<500 lymphocytes/mm\^3, neutrophil counts \<1000 neutrophils/mm\^3, platelet counts \<100000 platelets/mm\^3, any single hemoglobin (hg) value \<8 g/dL and any single hemoglobin value drops \>=2 g/dL below baseline. Number of Participants With serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported.
| Participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Serious Infections | 0 | 1 |
| Cytopenia: Lymphocyte counts <500 lymphocytes/mm^3 | 0 | 0 |
| Cytopenia:Neutrophil counts <1000 neutrophils/mm^3 | 0 | 2 |
| Cytopenia: Platelet counts <100,000 platelets/mm^3 | 1 | 0 |
| Cytopenia: Any single hemoglobin value <8 g/dL | 0 | 0 |
| Cytopenia: hg value drops >=2 g/dL below baseline | 3 | 7 |
| Malignancies | 0 | 0 |
| Cardiovascular Diseases | 0 | 0 |
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Day 1 was summarized and reported using number of participants in each stage.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Stage 1 | 73 |
| Stage 2 | 21 |
| Stage 3 | 25 |
| Stage 4 | 47 |
| Stage 5 | 52 |
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males) were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Week 44 was summarized and reported using number of participants in each stage.
| Participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Stage 1 | 13 | 7 |
| Stage 2 | 8 | 7 |
| Stage 3 | 8 | 3 |
| Stage 4 | 14 | 4 |
| Stage 5 | 13 | 17 |
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. Tanner Stage for Breast at Day 1 was summarized and reported using number of participants in each stage.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Stage 1 | 42 |
| Stage 2 | 19 |
| Stage 3 | 28 |
| Stage 4 | 34 |
| Stage 5 | 40 |
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. Tanner Stage for Breast at Week 44 was summarized and reported using number of participants in each stage.
| Participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Stage 1 | 6 | 8 |
| Stage 2 | 8 | 2 |
| Stage 3 | 7 | 2 |
| Stage 4 | 13 | 3 |
| Stage 5 | 9 | 13 |
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume \< 4 ml or long axis \< 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: \> 20 ml (or \> 4.5 cm long). Tanner Stage for genitalia at Day 1 was summarized and reported using number of participants in each stage.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Stage 1 | 24 |
| Stage 2 | 6 |
| Stage 3 | 8 |
| Stage 4 | 11 |
| Stage 5 | 6 |
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume \< 4 ml or long axis \< 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: \> 20 ml (or \> 4.5 cm long). Tanner Stage for genitalia at Week 44 was summarized and reported using number of participants in each stage.
| Participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Stage 1 | 5 | 0 |
| Stage 2 | 0 | 5 |
| Stage 3 | 2 | 0 |
| Stage 4 | 5 | 1 |
| Stage 5 | 1 | 4 |
Criteria: Hemoglobin(Hg),hematocrit erythrocytes(Ery); \<0.8\*lower limit of normal (LLN), Ery. Mean Corpuscular Volume; \<0.9\*LLN, \>1.1\*upper limit of normal (ULN), Platelets; \<0.5\*LLN, \>1.75\*ULN, Leukocytes (leu); \<0.6\*LLN, \>1.5\*ULN, Lymphocytes (Ly), Ly/leu, Neutrophils, Neutrophils/leu \<0.8\*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu \>1.2\*ULN, Ery Sedimentation Rate \>1.5\*ULN. Bilirubin, Indirect Bilirubin \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase, Alkaline Phosphatase \>3.0\*ULN, Albumin \>1.2\*ULN, Creatinine \>1.3\*ULN, HDL Cholesterol (Chol)\<0.8\*LLN, LDL Chol, LDL Chol Friedewald Est PEG \>1.2\*ULN, Triglycerides \>1.3\*ULN, Calcium \<0.9\*LLN, Bicarbonate \<0.9\*LLN, Glucose \>1.5\*ULN, Creatine Kinase \>2.0\*ULN, C Reactive Protein \>1.1\*ULN, Chol \>1.3\*ULN. Urinalysis: Specific Gravity \>1.030, Glucose, Ketones, Protein, Hg, Nitrite, Leu Esterase \>=1, Ery, Leu \>=20, Hyaline Casts \>1.Only those category in which at least 1 participant had data is reported.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Hemoglobin (<0.8* LLN) | 1 |
| Hematocrit (<0.8* LLN) | 1 |
| Erythrocytes (<0.8* LLN) | 2 |
| Ery. Mean Corpuscular Volume (<0.9*LLN) | 3 |
| Ery. Mean Corpuscular Volume (>1.1*ULN ) | 4 |
| Platelets (<0.5*LLN) | 1 |
| Platelets (>1.75*ULN) | 2 |
| Leukocytes (<0.6*LLN) | 1 |
| Leukocytes (>1.5*ULN) | 2 |
| Lymphocytes (<0.8*LLN) | 7 |
| Lymphocytes (>1.2*ULN) | 2 |
| Lymphocytes/Leukocytes (<0.8*LLN) | 15 |
| Lymphocytes/Leukocytes (>1.2*ULN) | 20 |
| Neutrophils (<0.8*LLN) | 8 |
| Neutrophils (>1.2*ULN) | 18 |
| Neutrophils/Leukocytes (<0.8*LLN) | 19 |
| Basophils/Leukocytes (>1.2*ULN) | 37 |
| Eosinophils (>1.2*ULN) | 53 |
| Eosinophils/Leukocytes (>1.2*ULN) | 32 |
| Monocytes (>1.2*ULN) | 3 |
| Monocytes/Leukocytes (>1.2*ULN) | 38 |
| Ery. Sedimentation Rate (>1.5*ULN) | 65 |
| Bilirubin (>1.5*ULN) | 1 |
| Indirect Bilirubin (>1.5*ULN) | 1 |
| Aspartate Aminotransferase (AST) (>3.0*ULN) | 4 |
| Alanine Aminotransferase (ALT) (>3.0*ULN) | 5 |
| GGT (>3.0*ULN) | 1 |
| Alkaline Phosphatase (>3.0*ULN) | 1 |
| Albumin (>1.2*ULN) | 1 |
| Creatinine (>1.3*ULN) | 1 |
| HDL Cholesterol (<0.8*LLN) | 2 |
| LDL Cholesterol (>1.2*ULN) | 4 |
| LDL Chol Friedewald Est PEG (>1.2*ULN) | 1 |
| Triglycerides (>1.3*ULN) | 27 |
| Calcium (<0.9*LLN) | 1 |
| Bicarbonate (<0.9*LLN) | 10 |
| Glucose (>1.5*ULN) | 2 |
| Creatine Kinase (>2.0*ULN) | 12 |
| C Reactive Protein (>1.1*ULN) | 122 |
| Cholesterol (>1.3*ULN) | 2 |
| Specific Gravity (>1.030) | 32 |
| URINE Glucose (>=1) | 1 |
| Ketones (>=1) | 11 |
| URINE Protein (>=1) | 9 |
| URINE Hemoglobin (>=1) | 48 |
| Nitrite (>=1) | 6 |
| Leukocyte Esterase (>=1) | 59 |
| URINE Erythrocytes (>=1) | 23 |
| URINE Leukocytes (>=20) | 16 |
| Hyaline Casts (>1) | 1 |
Criteria: Hg, hematocrit Ery; \<0.8\* LLN, Ery. Mean Corpuscular Volume; \<0.9\*LLN, \>1.1\* ULN, Platelets; \<0.5\*LLN, \>1.75\*ULN, leu; \<0.6\*LLN, \>1.5\*ULN, Ly, Ly/leu, Neutrophils, Neutrophils/leu \<0.8\*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu \>1.2\*ULN, Prothrombin Time \>1.1\*ULN, Ery Sedimentation Rate \>1.5\*ULN. Bilirubin, Direct Bilirubin, Indirect Bilirubin \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase (GGT), Alkaline Phosphatase \>3.0\*ULN, Albumin \>1.2\*ULN, Creatinine \>1.3\*ULN, HDL Cholesterol (Chol)\<0.8\*LLN, LDL Chol, LDL Chol Friedewald Est PEG \>1.2\*ULN, Triglycerides \>1.3\*ULN, Calcium \<0.9\*LLN, Bicarbonate \<0.9\*LLN, Glucose \>1.5\*ULN, Creatine Kinase \>2.0\*ULN, C Reactive Protein \>1.1\*ULN, Chol \>1.3\*ULN. Urinalysis: Specific Gravity \>1.030, pH \>8, urine Glucose, Ketones, Protein, Hg, Nitrite, Leu Esterase \>=1, Ery, Leu \>=20, Hyaline Casts \>1.Only those category in which at least 1 participant had data is reported.
| Participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Hemoglobin (<0.8*LLN) | 1 | 3 |
| Hematocrit (<0.8*LLN) | 0 | 2 |
| Erythrocytes (<0.8*LLN) | 0 | 2 |
| Ery. Mean Corpuscular Volume (<0.9*LLN) | 2 | 1 |
| Ery. Mean Corpuscular Volume (>1.1*ULN) | 1 | 2 |
| Platelets (<0.5*LLN) | 1 | 0 |
| Leukocytes (<0.6*LLN) | 0 | 1 |
| Leukocytes (>1.5*ULN) | 1 | 0 |
| Lymphocytes (<0.8*LLN) | 5 | 1 |
| Lymphocytes (>1.2*ULN) | 1 | 0 |
| Lymphocytes/Leukocytes (<0.8*LLN) | 9 | 5 |
| Lymphocytes/Leukocytes (>1.2*ULN) | 5 | 7 |
| Neutrophils (<0.8*LLN) | 1 | 3 |
| Neutrophils (>1.2*ULN) | 7 | 5 |
| Neutrophils/Leukocytes (<0.8*LLN) | 5 | 6 |
| Basophils (>1.2*ULN) | 1 | 0 |
| Basophils/Leukocytes (>1.2*ULN) | 14 | 15 |
| Eosinophils (>1.2*ULN) | 27 | 18 |
| Eosinophils/Leukocytes (>1.2*ULN) | 21 | 14 |
| Monocytes (>1.2*ULN) | 2 | 2 |
| Monocytes/Leukocytes (>1.2*ULN) | 18 | 19 |
| Prothrombin Time (>1.1*ULN) | 0 | 1 |
| Ery. Sedimentation Rate (>1.5*ULN) | 26 | 19 |
| Bilirubin (>1.5*ULN) | 1 | 0 |
| Direct Bilirubin (>1.5*ULN) | 1 | 0 |
| Indirect Bilirubin (>1.5*ULN) | 1 | 0 |
| Alanine Aminotransferase(>3.0*ULN) | 1 | 2 |
| GGT (>3.0*ULN) | 1 | 0 |
| HDL Cholesterol (<0.8*LLN) | 0 | 2 |
| Triglycerides (>1.3*ULN) | 8 | 6 |
| Potassium (>1.1*ULN) | 1 | 0 |
| Calcium (<0.9*LLN ) | 1 | 1 |
| Glucose (>1.5*ULN) | 1 | 0 |
| Creatine Kinase (>2.0*ULN) | 2 | 2 |
| C Reactive Protein (>1.1*ULN) | 44 | 47 |
| Specific Gravity (>1.030) | 12 | 7 |
| pH (>8) | 0 | 1 |
| URINE Glucose (>=1) | 1 | 1 |
| Ketones (>=1) | 7 | 10 |
| URINE Protein (>=1) | 4 | 4 |
| URINE Hemoglobin (>=1) | 25 | 11 |
| Nitrite (>=1) | 3 | 6 |
| Leukocyte Esterase (>=1) | 26 | 25 |
| URINE Erythrocytes (>=20) | 10 | 6 |
| URINE Leukocytes (>=20) | 6 | 6 |
| Hyaline Casts (>1) | 1 | 1 |
| Granular Casts (>1) | 0 | 1 |
| Bicarbonate (<0.9*LLN) | 0 | 2 |
Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Abdomen: Baseline | 1 |
| Abdomen: Week 2 | 2 |
| Abdomen: Week 4 | 3 |
| Abdomen: Week 8 | 2 |
| Abdomen: Week 12 | 2 |
| Abdomen: Week 18 | 1 |
| Ears: Baseline | 5 |
| Ears: Week 2 | 0 |
| Ears: Week 4 | 0 |
| Ears: Week 8 | 0 |
| Ears: Week 12 | 0 |
| Ears: Week 18 | 3 |
| Extremities: Baseline | 49 |
| Extremities: Week 2 | 43 |
| Extremities: Week 4 | 35 |
| Extremities: Week 8 | 30 |
| Extremities: Week 12 | 28 |
| Extremities: Week 18 | 23 |
| Eyes: Baseline | 2 |
| Eyes: Week 2 | 0 |
| Eyes: Week 4 | 0 |
| Eyes: Week 8 | 0 |
| Eyes: Week 12 | 0 |
| Eyes: Week 18 | 2 |
| General appearance: Baseline | 16 |
| General appearance: Week 2 | 0 |
| General appearance: Week 4 | 1 |
| General appearance: Week 8 | 2 |
| General appearance: Week 12 | 0 |
| General appearance: Week 18 | 5 |
| Head: Baseline | 3 |
| Head: Week 2 | 0 |
| Head: Week 4 | 0 |
| Head: Week 8 | 0 |
| Head: Week 12 | 0 |
| Head: Week 18 | 4 |
| Heart: Baseline | 0 |
| Heart: Week 2 | 0 |
| Heart: Week 4 | 0 |
| Heart: Week 8 | 2 |
| Heart: Week 12 | 0 |
| Heart: Week 18 | 0 |
| Lungs: Baseline | 1 |
| Lungs: Week 2 | 1 |
| Lungs: Week 4 | 0 |
| Lungs: Week 8 | 1 |
| Lungs: Week 12 | 1 |
| Lungs: Week 18 | 0 |
| Lymph nodes: Baseline | 2 |
| Lymph nodes: Week 2 | 5 |
| Lymph nodes: Week 4 | 5 |
| Lymph nodes: Week 8 | 5 |
| Lymph nodes: Week 12 | 3 |
| Lymph nodes: Week 18 | 4 |
| Neurological: Baseline | 4 |
| Neurological: Week 2 | 1 |
| Neurological: Week 4 | 0 |
| Neurological: Week 8 | 0 |
| Neurological: Week 12 | 0 |
| Neurological: Week 18 | 4 |
| Nose: Baseline | 0 |
| Nose: Week 2 | 0 |
| Nose: Week 4 | 0 |
| Nose: Week 8 | 0 |
| Nose: Week 12 | 0 |
| Nose: Week 18 | 5 |
| Skin: Baseline | 27 |
| Skin: Week 2 | 0 |
| Skin: Week 4 | 1 |
| Skin: Week 8 | 1 |
| Skin: Week 12 | 0 |
| Skin: Week 18 | 12 |
| Throat: Baseline | 1 |
| Throat: Week 2 | 0 |
| Throat: Week 4 | 0 |
| Throat: Week 8 | 0 |
| Throat: Week 12 | 0 |
| Throat: Week 18 | 6 |
Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion.
| Participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Abdomen: Week 18 | 0 | 1 |
| Abdomen: Week 20 | 1 | 1 |
| Abdomen: Week 24 | 1 | 1 |
| Abdomen: Week 28 | 0 | 0 |
| Abdomen: Week 32 | 0 | 0 |
| Abdomen: Week 36 | 0 | 0 |
| Abdomen: Week 40 | 0 | 0 |
| Abdomen: Week 44 | 0 | 0 |
| Ears: Week 18 | 3 | 0 |
| Ears: Week 20 | 0 | 0 |
| Ears: Week 24 | 0 | 0 |
| Ears: Week 28 | 0 | 0 |
| Ears: Week 32 | 0 | 0 |
| Ears: Week 40 | 0 | 1 |
| Ears: Week 44 | 0 | 0 |
| Extremities: Week 18 | 9 | 12 |
| Extremities: Week 20 | 11 | 14 |
| Extremities: Week 24 | 5 | 7 |
| Extremities: Week 28 | 6 | 6 |
| Extremities: Week 32 | 1 | 8 |
| Extremities: Week 36 | 2 | 6 |
| Extremities: Week 40 | 3 | 6 |
| Extremities: Week 44 | 3 | 7 |
| Eyes: Week 18 | 2 | 0 |
| Eyes: Week 20 | 0 | 0 |
| Eyes: Week 24 | 0 | 0 |
| Eyes: Week 28 | 0 | 0 |
| Eyes: Week 32 | 0 | 0 |
| Eyes: Week 40 | 0 | 0 |
| Eyes: Week 44 | 1 | 0 |
| General appearance: Week 18 | 2 | 3 |
| General appearance: Week 20 | 1 | 1 |
| General appearance: Week 24 | 0 | 0 |
| General appearance: Week 28 | 0 | 0 |
| General appearance: Week 32 | 0 | 0 |
| General appearance: Week 40 | 0 | 0 |
| General appearance: Week 44 | 1 | 0 |
| Head: Week 18 | 3 | 1 |
| Head: Week 20 | 0 | 0 |
| Head: Week 24 | 0 | 0 |
| Head: Week 28 | 0 | 0 |
| Head: Week 32 | 0 | 1 |
| Head: Week 40 | 1 | 0 |
| Head: Week 44 | 0 | 0 |
| Heart: Week 18 | 0 | 0 |
| Heart: Week 20 | 0 | 0 |
| Heart: Week 24 | 0 | 0 |
| Heart: Week 28 | 0 | 0 |
| Heart: Week 32 | 0 | 0 |
| Heart: Week 36 | 0 | 0 |
| Heart: Week 40 | 0 | 0 |
| Heart: Week 44 | 0 | 0 |
| Lungs: Week 18 | 0 | 0 |
| Lungs: Week 20 | 1 | 0 |
| Lungs: Week 24 | 1 | 0 |
| Lungs: Week 28 | 1 | 0 |
| Lungs: Week 32 | 0 | 0 |
| Lungs: Week 36 | 0 | 0 |
| Lungs: Week 40 | 0 | 1 |
| Lungs: Week 44 | 0 | 0 |
| Lymph nodes: Week 18 | 3 | 1 |
| Lymph nodes: Week 20 | 3 | 0 |
| Lymph nodes: Week 24 | 2 | 1 |
| Lymph nodes: Week 28 | 1 | 0 |
| Lymph nodes: Week 32 | 1 | 1 |
| Lymph nodes: Week 36 | 1 | 0 |
| Lymph nodes: Week 40 | 2 | 0 |
| Lymph nodes: Week 44 | 1 | 1 |
| Neurological: Week 18 | 3 | 1 |
| Neurological: Week 20 | 1 | 0 |
| Neurological: Week 24 | 0 | 0 |
| Neurological: Week 28 | 0 | 0 |
| Neurological: Week 32 | 0 | 0 |
| Neurological: Week 40 | 0 | 0 |
| Neurological: Week 44 | 1 | 1 |
| Nose: Week 18 | 4 | 0 |
| Nose: Week 20 | 0 | 0 |
| Nose: Week 24 | 0 | 0 |
| Nose: Week 28 | 0 | 0 |
| Nose: Week 32 | 0 | 0 |
| Nose: Week 40 | 0 | 0 |
| Nose: Week 44 | 1 | 0 |
| Skin: Week 18 | 8 | 4 |
| Skin: Week 20 | 3 | 1 |
| Skin: Week 24 | 1 | 0 |
| Skin: Week 28 | 0 | 0 |
| Skin: Week 32 | 0 | 0 |
| Skin: Week 40 | 1 | 1 |
| Skin: Week 44 | 4 | 2 |
| Throat: Week 18 | 4 | 2 |
| Throat: Week 20 | 0 | 1 |
| Throat: Week 24 | 0 | 0 |
| Throat: Week 28 | 0 | 0 |
| Throat: Week 32 | 0 | 0 |
| Throat: Week 40 | 0 | 0 |
| Throat: Week 44 | 0 | 0 |
Vital Sign Abnormalities criteria included: sitting diastolic blood pressure millimeters of Mercury (mmHG) of \<50 mmHg, sitting pulse rate beats per minute (bpm) of \<40 or 120 bpm, sitting systolic blood pressure (mmHG) of \<90 mmHg, supine diastolic blood pressure (mmHG) of \<50 mmHg, supine pulse rate (BPM) of \<40 bpm or \>120 bpm, supine systolic blood pressure (mmHG) of 90 mmHg.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Sitting diastolic BP ([mmHg]): <50 mmHg | 0 |
| Sitting pulse rate (bpm): <40 bpm | 0 |
| Sitting pulse rate (bpm): >120 bpm | 5 |
| Sitting systolic BP (mmHg): <90 mmHg | 0 |
| Supine diastolic BP (mmHg): <50 mmHg | 2 |
| Supine pulse rate (bpm): <40 bpm | 0 |
| Supine pulse rate (bpm): >120 bpm | 0 |
| Supine systolic BP (mmHg): <90 mmHg | 2 |
Vital Sign Abnormalities criteria included: diastolic blood pressure (mmHG) of \<50 mmHg, Pulse rate (BPM) of \<40 bpm or \>120 bpm, sitting diastolic blood pressure (mmHG) of \<50 mmHg, sitting pulse rate beats per minute (bpm) of \<40 bpm or \>120 bpm, sitting systolic blood pressure (mmHG) of \<90 mmHg, supine diastolic blood pressure (mmHG) of \<50 mmHg, supine pulse rate (BPM) of \<40 bpm or \>120 bpm, supine systolic blood pressure (mmHG) of \<90 mmHg, systolic blood pressure (mmHG) of \<90 mmHg.
| Participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Diastolic BP (mmHg): <50 mmHg | 0 | 0 |
| Pulse rate (bpm): <40 bpm | 0 | 0 |
| Pulse rate (bpm): >120 bpm | 0 | 0 |
| Sitting diastolic BP (mmHg): <50 mmHg | 0 | 0 |
| Sitting pulse rate (bpm): <40 bpm | 0 | 0 |
| Sitting pulse rate (bpm): >120 bpm | 0 | 1 |
| Sitting systolic BP (mmHg): <90 mmHg | 0 | 0 |
| Supine diastolic BP (mmHg): <50 mmHg | 0 | 0 |
| Supine pulse rate (bpm): <40 bpm | 0 | 0 |
| Supine pulse rate (bpm): >120 bpm | 0 | 0 |
| Supine systolic BP (mmHg): <90 mmHg | 1 | 0 |
| Systolic BP (mmHg): <90 mmHg | 0 | 0 |
Change in vital Signs included: Sitting diastolic blood pressure \[mmHG\]: \>=20mmHg increase from baseline (IFB) and \>= 20mmHg decrease from baseline (DFB). Sitting systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB. Supine diastolic blood pressure mmHG: \>= 20mmHg IFB and \>= 20mmHg DFB. Supine systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB.
| Participants | Tofacitinib: Open-Label Phase |
|---|---|
| Sitting diastolic BP: >= 20mmHg IFB | 9 |
| Sitting diastolic BP: >= 20mmHg DFB | 14 |
| Sitting systolic BP: >= 30mmHg IFB | 2 |
| Sitting systolic BP: >= 30mmHg DFB | 5 |
| Supine diastolic BP: >= 20mmHg IFB | 0 |
| Supine diastolic BP: >= 20mmHg DFB | 3 |
| Supine systolic BP: >= 30mmHg IFB | 0 |
| Supine systolic BP: >= 30mmHg DFB | 3 |
Change in vital Signs included: Sitting diastolic blood pressure (mmHG): \>=20mmHg IFB and \>= 20mmHg DFB. Sitting systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB. Supine diastolic blood pressure mmHG: \>= 20mmHg IFB and \>= 20mmHg DFB. Supine systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB.
| Participants | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|
| Sitting diastolic BP: >= 20mmHg IFB | 9 | 3 |
| Sitting diastolic BP: >= 20mmHg DFB | 7 | 9 |
| Sitting systolic BP: >= 30mmHg IFB | 3 | 4 |
| Sitting systolic BP: >= 30mmHg DFB | 0 | 2 |
| Supine diastolic BP: >= 20mmHg IFB | 0 | 0 |
| Supine diastolic BP: >= 20mmHg DFB | 0 | 0 |
| Supine systolic BP: >= 30mmHg IFB | 0 | 0 |
| Supine systolic BP: >= 30mmHg DFB | 0 | 0 |
Collected over From the first dose of study drug up to week 44. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib: Open-Label Phase | 0/225 (0%) | 7/225 (3.1%) | 108/225 (48%) |
| Tofacitinib: Double Blind Phase | 0/88 (0%) | 1/88 (1.1%) | 57/88 (64.8%) |
| Placebo | 0/85 (0%) | 2/85 (2.4%) | 57/85 (67.1%) |
| Event | Tofacitinib: Open-Label Phase | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|---|
| AppendicitisInfections and infestations | 1/225 | 0/88 | 1/85 |
| IntussusceptionGastrointestinal disorders | 0/225 | 0/88 | 1/85 |
| Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders | 0/225 | 0/88 | 1/85 |
| Pilonidal sinus repairSurgical and medical procedures | 0/225 | 1/88 | 0/85 |
| Crohn's diseaseGastrointestinal disorders | 1/225 | 0/88 | 0/85 |
| DiarrhoeaGastrointestinal disorders | 1/225 | 0/88 | 0/85 |
| VomitingGastrointestinal disorders | 1/225 | 0/88 | 0/85 |
| Condition aggravatedGeneral disorders | 1/225 | 0/88 | 0/85 |
| Epidural empyemaInfections and infestations | 1/225 | 0/88 | 0/85 |
| PneumoniaInfections and infestations | 1/225 | 0/88 | 0/85 |
| Event | Tofacitinib: Open-Label Phase | Tofacitinib: Double Blind Phase | Placebo |
|---|---|---|---|
| Disease progressionGeneral disorders | 5/225 | 8/88 | 13/85 |
| Upper respiratory tract infectionInfections and infestations | 24/225 | 13/88 | 9/85 |
| Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders | 6/225 | 3/88 | 11/85 |
| NasopharyngitisInfections and infestations | 10/225 | 7/88 | 3/85 |
| HeadacheNervous system disorders | 16/225 | 2/88 | 6/85 |
| NauseaGastrointestinal disorders | 13/225 | 0/88 | 0/85 |
| VomitingGastrointestinal disorders | 12/225 | 0/88 | 4/85 |
| PyrexiaGeneral disorders | 11/225 | 4/88 | 1/85 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/225 | 2/88 | 4/85 |
| SinusitisInfections and infestations | 0/225 | 4/88 | 1/85 |
The open-label phase full analysis set (OLFAS) consisted of all participants who were enrolled into open-label phase of the study and received at least one dose of study medication in open-label phase.
| Age, Continuous(Years) | Tofacitinib: Open-Label Phase |
|---|---|
| Mean | 11.92 ± 4.06 |
| Sex: Female, Male(Participants) | Tofacitinib: Open-Label Phase |
|---|---|
| Female | 169 |
| Male | 56 |
| Ethnicity (NIH/OMB)(Participants) | Tofacitinib: Open-Label Phase |
|---|---|
| Hispanic or Latino | 64 |
| Not Hispanic or Latino | 161 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Tofacitinib: Open-Label Phase |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 196 |
| More than one race | 0 |
| Unknown or Not Reported | 24 |
Showing the first 100 of 103 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2016 to primary completion in May 2019, 35 months.
Results were first posted in Feb 2020, 9 months after primary completion.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 35 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib